Insulin-like growth factors (IGFs) 1 I and II regulate cellular proliferation, survival, and differentiation. These actions are carried out by locally produced IGFs, which are supplemented by IGFs derived from the circulation. Partition of IGFs between the vascular and cellular interstitial compartments is determined in part by members of a family of high affinity IGFbinding proteins (1, 2) . IGFBPs modulate IGF-I and IGF-II bioavailability in part by competitive binding and sequestration and prevention of appropriate interaction with cell membrane receptors. In addition, some IGFBPs bind to components of the extracellular matrix (IGFBP-2, -3, and -5) or the cell membrane (IGFBP-1, -2, -3, and -5), thus providing a mechanism to concentrate IGFs within discrete tissue compartments (2) . Free IGFs are released by proteolytic cleavage of the respective IGFBP through the action of specific proteases (3) (4) (5) (6) . Proteases that cleave IGFBP-2 (7), IGFBP-3 (8, 9), IGFBP-4 (4 -6), and IGFBP-5 (10 -12) have been reported.
IGFBP-4, which exists in biological fluids as a 28-kDa glycosylated and/or a 24-kDa non-glycosylated form (13, 14) is abundant in serum and expressed in many different tissues (2, 15) . IGFBP-4 does not bind to the cell membrane and is found associated with connective tissue, although the precise nature of this interaction is not known. It consistently inhibits IGFmediated cell proliferation of all cell types tested in vitro (13) (14) (15) (16) . Regulated proteolysis of IGFBP-4 results in fragments with reduced affinity for IGFs and therefore releases the growth factor for interaction with cell membranes (13) (14) (15) 17) . IGFBP-4 is also the most abundant IGFBP expressed in the rat artery wall in vivo and is the dominant IGFBP secreted by rat adult vascular smooth muscle cells in vitro (18) . After arterial injury, IGFBP-4 mRNA abundance increases, as does the activity of the IGFBP-4 protease, resulting in stable steady-state levels of the IGFBP-4 protein (18) . Though increased expression of IGFBP-4 may serve to inhibit IGF-I, if this is coupled with increased proteolytic cleavage then this may ultimately serve to release increased amounts of active IGF-I. The protease(s) that cleave IGFBP-4 are found ubiquitously, including the conditioned medium of cultured fibroblasts, decidual cells, osteoblasts, and SMC and in biological fluids such as pregnancy serum and CSF (14, 19 -21) . Recently, pregnancy-associated plasma protein-A (PAPP-A) has been identified as a protease for IGFBP-4 (22) , and this protein is expressed in smooth muscle cells (3, 23) .
The biochemistry of IGFBP-4 cleavage has been examined through analyses of the fragments produced following exposure to IGFBP-4 protease from various sources and from the effects of limited mutations on protease susceptibility (6, 24 -26) . These experiments clearly identify a 13-amino acid domain within the middle of the molecule as the principal site of cleavage. This region is largely conserved among mammalian species of this binding protein but is unique to IGFBP-4 among all IGFBP family members, offering a biochemical explanation for the apparent specificity of the IGFBP-4 proteases. This region is rich in basic amino acid residues that could be subject to tryptic-like cleavage. Attempts to further define which bonds within this domain are initially cleaved have produced somewhat discordant results. Some reports indicate residues 120/ 121 are most critical while others describe the 130/132 basic amino acids as the primary cleavage site (6, 24, 25, (27) (28) (29) . These differences could be caused by secondary site use by the protease, intraspecies differences, or more than one IGFBP-4 protease that attacks this highly charged domain.
Our objective was to examine the role of IGFBP-4 proteolysis in vivo, using a mutant IGFBP-4 that would be largely insensitive to degradation by physiological IGFBP-4 proteases. We show that substitution of the seven basic residues in the midregion of IGFBP-4 by alanine renders the protein resistant to proteolysis in vitro and in vivo, without affecting its IGF binding affinity. When expressed at equivalent levels in smooth muscle cells of transgenic mice, protease-resistant IGFBP-4 results in greater growth inhibition than native IGFBP-4, supporting a role for IGFBP-4 proteolysis in the regulation of IGF-1 action.
EXPERIMENTAL PROCEDURES
Production of IGFBP-4 Mutant cDNA (IGFBP-4.7A)-A cDNA construct encoding a mutant IGFBP-4 in which all seven basic residues between Lys-120 and Lys-132 were exchanged for Ala residues was produced by stepwise mutagenesis of a cDNA construct originally provided by S. Shimasaki et al. (30) (Fig. 1) . The previously created K120A IGFBP-4 (6) was mutated by PCR mutagenesis to K120A/H121A using the oligonucleotide 5Ј-ACTTTGGCCATAGCCGCCTGCAGGC-3Ј and transferred to pcDNA 3.0 (Invitrogen, Carlsbad, CA) using previously described methodology (6) . Next the codon for residue Lys-124 was changed to Ala using the Chameleon double-stranded mutagenesis kit (Stratagene, Inc.), employing the mutagenesis primer 5Ј-TATGGC-CGCGGTGAGAGATGCGAGCAAGATGA-3Ј that introduced a SacII restriction site. The final four residues were altered by generating a mutant PCR fragment that was cloned into the SacII and XbaI restriction sites of the aforementioned construct. The mutagenic oligonucleotide for this step was 5Ј-GGCTATGGCCGCGGTGGCAGATGC-GAGCGCGATGGCGGTTGTGGGGACAC-3Ј. Fidelity of IGFBP-4.7A construct was verified by automated sequencing of the entire cDNA. This cDNA construct, IGFBP-4.7A, was ultimately expressed in vitro and in vivo for the experiments described.
Determination of Sensitivity of SMP8-IGFBP-4.7A to the SMC IG-FBP-4
Protease-To analyze the properties of the mutant IGFBP-4.7A protein, we used B104ns cells, a subclone of the B104 rat neuroblastoma cell line with low expression levels of endogenous native IGFBP-4 as host for transfection experiments (14) . IGFBP-4 proteins that contained C-terminal Myc-His tags were produced by stably transfecting B104ns cells with pcDNA 3.1 plasmids (Invitrogen) into which native and IGFBP-4.7A cDNAs had been cloned. Plasmid-bearing cells were grown to confluency in medium containing 800 ng/ml G418, and conditioned medium was collected, heated to inactivate endogenous proteases, and concentrated by Centricon-10 filters (Millipore, Bedford, MA). An aliquot of the conditioned medium was exposed to adult SMC medium for 24 and 40 h in buffer (50 mM Tris, 2 mM CaCl 2 , 50 M ZnSO 4 , 0.002% bovine serum albumin, pH 7.5) containing 100 ng/ml IGF-1. Susceptibility to proteolysis was assessed following SDS-PAGE of the reaction mixture by immunoblot using an anti-Myc-specific antibody.
Determination of Binding Affinity for IGF-I of Native IGFBP-4 and IGFBP-4.7A-The IGFBP-4.7A cDNA was cloned into the pcDNA3.1 expression plasmid, which was subsequently stably transfected into B104ns cells. The expressed protein had a 9-amino acid C-terminal extension in addition to the 7 mutated residues. Cells were maintained in G418 and expressed IGFBP-4.7A was purified using affinity chromatography. This preparation was compared with native IGFBP-4 isolated from B104ns medium as previously described (13). 10 ng of the purified binding protein were then affinity cross-linked to 125 I-IGF-I using the bifunctional cross-linking agent disuccinimidyl suberate in the presence of graded amounts of unlabeled IGF-I, as described (13) . The products of the competitive inhibition experiment were analyzed by SDS-PAGE, and the signal corresponding to IGFBP-4 was quantified by phosphorimaging.
Generation of Transgenic Mice-Mice with targeted overexpression of native IGFBP-4 in smooth muscle have been previously described (31) . We used an identical approach to target expression of IGFBP-4 7A selectively to smooth muscle cells. Briefly, the cDNA for the IGFBP-4 protease-resistant mutant was cloned downstream of the SMP8 fragment of the mouse SM ␣-actin gene promoter, as previously reported (31) . The SMP8-IGFBP-4.7A construct was released from Puc18 by digestion with KpnI and NotI and then gel-purified (31) . Male pronuclei of fertilized eggs from FVB-N mouse strains were microinjected with 2 pl of DNA at the transgenic mouse facility of the University of Cincinnati. Microinjected eggs were implanted into the oviduct of pseudopregnant female mice and carried to term. Positive founders were identified by Southern blotting and bred to wild-type FVB-N mice for propagation of the line. Mouse tail tips were cut at 3 weeks of age, and the transgene identified by Southern blotting of EcoR1-digested DNA hybridized with a rat IGFBP-4 cDNA probe labeled by random priming (Prime-It, Stratagene). The transgene was identified by the presence of a unique ϳ3.0-kb band. Routine screening of established SMP8-BP-4 or SMP8-IGFBP-4.7A lines was performed by PCR of tail DNA using the following oligonucleotide primers: forward, 5Ј-CCTGTGACACTC-CCGCTCTTTG-3Ј; reverse, 5Ј-AGGGCAGTGGATGGCTTCGTC-3Ј; endogenous c-Fos gene primers: forward, 5Ј-GGCTGGCCCTGTAT-TCCTGAT-3Ј; reverse, 5Ј-TCTTCTGACCCTTCCCTACTGAGC-3Ј. Amplification was performed under standard conditions using Redtaq polymerase (Sigma) with the following cycle parameters: initial hotstart denaturation, 95°C, 5 min followed by 40 cycles of 94°C, 1 min; 64°C, 1 min; and 72°C, 1 min.
Five separate SMP8-IGFBP-4.7A lines were propagated and three of them selected for more extensive analysis. Expression levels and phenotypic changes in SMP8-IGFBP-4.7A mice were compared with those in the previously reported SMP8-IGFBP-4 lines 23942, 23928, 23926, and 23945 (31) .
Determination of Tissue Content of IGFBPs-Transgene mRNA levels were determined by Northern blotting. Quantification was performed by phosphorimaging and adjusted to that of an appropriate internal standard. The same lines were then used for analysis of IG-FBP-4 protein content by Western immunoblotting (31, 32) . Briefly, tissues were homogenized in PBS with 12 mM EDTA and 1 mM phenylmethylsulfonyl fluoride in a Polytron (model PT3000) at full speed on ice. Extracts were centrifuged at 100,000 ϫ g for 1 h at 4°C, and the supernatant was further concentrated in a Centricon-3 device (Amicon, Inc., Beverly, MA). Aliquots of the concentrated extracts were taken for protein assay. The extracts were run on 10% Laemmli gels under reducing conditions. The blots were blocked with a Tris-buffered saline solution containing 0.05% Tween 20 and nonfat dry milk and incubated with either 1:5000 rabbit anti-rat IGFBP4 antibody (516.F) generated against residues 81-100 of the rodent sequence (6, 30) in the same blocking solution plus 0.01% thimerosal at room temperature for 16 h. IGFBP-4 was visualized by standard ECL techniques as described (33) and quantified by phosphorimager.
Phenotypic Analysis-SMP8-IGFBP-4.7A mice from line 39208 had equivalent levels of IGFBP-4 in smooth muscle rich tissues to age and sex-matched SMP8-IGFBP-4 mice from line 23942, and these were selected for analysis of organ weights. To compare the two transgenic lines, animals were sacrificed at 10 weeks of age as previously described (31) . Briefly, transgenic mice and their nontransgenic littermates were killed by CO 2 asphyxiation. After obtaining body weight, blood was collected by cardiac puncture, and the serum was stored at Ϫ80°C until use. Organs of interest were dissected, rinsed in ice-cold PBS, tissueblotted, weighed, and immediately frozen in liquid nitrogen. Contents of stomach and small intestine were flushed out with PBS before weighing. A section of the arterial vessel from the aortic arch to the level of femoral bifurcation was excised and placed in PBS. Adhering fat and connective tissue from the adventitia were scraped off under surgical microscope, and the vessel was cleansed with PBS to remove any residual blood. Tissues were weighed after blotting away excess fluid.
RESULTS
Resistance of IGFBP-4.7A to Proteolytic Degradation-We first explored the relative cleavage resistance of IGFBP-4 mutants with discrete substitutions across the putative protease recognition domain (amino acids 120 -132). Purified alaninesubstituted mutants IGFBP-4.K120A/H121A or IGFBP-4.K120A/H121A/K124A were only partially resistant to cleavage by protease activity from either osteoblast or smooth muscle cell-conditioned medium (not shown). We therefore developed an IGFBP-4 mutant in which all seven basic residues between Lys-120 and Lys-132 were substituted. As shown in Fig. 2 , concentrated aliquots of smooth muscle cell-conditioned medium efficiently cleaved purified Myc-tagged native rat IG-FBP-4 but failed to degrade IGBP-4.7A in the presence of IGF-1.
Binding of IGF-I by IGFBP-4.7A-The goal of this study was to examine the contribution of IGFBP-4 degradation to IGF action in vivo. It was therefore important to demonstrate that the mutations introduced in the midregion of the molecule had not impaired IGF binding affinity. For this purpose, we purified IGFBP-4.7A and native IGFBP-4 from the conditioned medium of B104ns cells stably transfected with expression vectors for the respective binding protein. Equal amounts of native and mutant IGFBP-4 were then chemically cross-linked to 125 I-IGF-1 in the presence of graded concentrations of unlabeled IGF-1. The samples were subjected to SDS-PAGE and quantified by phosphorimager. Linear regression analysis showed comparable displacement of tracer by unlabeled ligand for both the wild-type and mutant forms of IGFBP-4, indicating that IGFBP-4.7A bound IGF normally (Fig. 3) .
Development of SMP8-IGFBP-4.7A Mice and Characterization of the Tissue Distribution of Expression-
To explore the function of the protease-resistant IGFBP-4 in vivo, we targeted its expression to smooth muscle cells of transgenic mice. We previously reported that targeted overexpression of native IG-FBP-4 under the control of the SM ␣-actin gene promoter was associated with smooth muscle hypoplasia (31) . The same approach was used to target expression of IGFBP-4.7A to smooth muscle cells. As shown in Fig. 4 , tissue distribution of the IGFBP-4.7A mRNA transgene was restricted to smooth muscle cell-rich tissues such as the aorta, bladder, stomach, intestine, and spleen. This recapitulates the pattern of expression previously reported for the SMP8-IGFBP-4 mice (31) and that of smooth muscle ␣-actin (31,32). Endogenous IGFBP-4 mRNA was maximal in the liver, spleen, and kidney. Expression of the IGFBP-4 transgenes (identified through their faster migration) did not affect endogenous IGFBP-4 mRNA abundance. Serum IGFBP-4 levels were not increased in either SMP8-IGFBP-4 or SMP8-IGFBP-4.7A mice as determined by Western ligand blotting, confirming that the products of the respective transgenes are largely confined to tissues of origin (not shown).
Increased Stability of the IGFBP-4.7A Protein in Vivo-If IGFBP-4.7A were resistant to endogenous proteases in vivo, then the tissues in which it is expressed should show greater accumulation of the protein relative to the abundance of the respective mRNA. To test this premise, we first quantified IGFBP-4 mRNA abundance in bladders from representative age-and sex-matched mice from four native IGFBP-4 and three IGFBP-4.7A transgenic lines, respectively. As shown in Fig. 5 , transgenic IGFBP-4 mRNA was highly expressed in bladder of all lines tested and far exceeded abundance of the endogenous transcript. Notably, bladders from mice derived from the three lines expressing the protease-resistant mutant contained markedly higher levels of immunoreactive IGFBP-4 than the lines overexpressing the native form of the protein (Fig. 6) . The IGFBP-4.7A immunoreactive band migrated significantly faster than native IGFBP-4, which was likely due to different interaction with the gel matrix. Altered electrophoretic mobility was not due to differences in glycosylation of the mutant protein as it persisted following digestion with N-glycanase (not shown). 
Phenotype of the Native versus Mutant IGFBP-4 Transgenic Lines Selected for Similar Protein Expression-
We next explored whether IGFBP-4.7A exerted greater growth inhibitory effects than native IGFBP-4 when expressed at equivalent levels in smooth muscle cell-rich tissues. For this purpose, we studied SMP8-IGFBP-4 line 23942 and SMP8-IGBBP-4.7A line 39208, because they had comparable immunoreactive IGFBP-4 levels (Figs. 6 and 7) . As previously reported, overexpression of native IGFBP-4 was associated with decreased wet weight of aorta, bladder, and stomach. Expression of comparable levels of the IGFBP-4 7A resulted in an even greater decrease of wet weight of the indicated tissues (Fig. 8A) . There was no significant difference in total weight of the animals or weight of any other organ (data not shown). Overexpression of IGFBP-4.7A was also associated with a significant shortening of the small intestine, whereas native IGFBP-4 was without effect (Fig. 8B) . DISCUSSION These studies demonstrate that basic residues between amino acids 120 and 135 are critical for IGFBP-4 proteolysis and can be replaced by alanine without significantly affecting IGF-I binding affinity. Preservation of IGF-I binding would be anticipated because the primary binding domain for IGF-I in IGFBP-4 was demonstrated to reside within a hydrophobic motif in the distal part of the conserved N terminus of the protein (29, 35) , in a similar region required for IGFBP-5 binding to IGF-I (36). The decision to develop an IGFBP-4 mutant with multiple substitutions within the cleavage domain was based on evidence that mutants with more discrete replacements at the precise putative cleavage site(s) could still be degraded by IGFBP-4 protease(s) in the conditioned media of several cell types. Conover et al. (37) reported that the IGFBP-4 protease(s) secreted by human fibroblasts and osteoblasts cleaved hIGFBP-4 between Met-135 and Lys-136 (equivalent to Met-131/Lys-132 of rIGFBP-4) (37) . Discrete substitutions at these sites resulted in an IGFBP-4 mutant with normal binding affinity to IGFs, and a relative, but not absolute, resistance to proteolysis. By contrast, in a previous report one of us found the primary cleavage domain of IGFBP-4 to reside between Lys-120/His-121. However, alanine substitution of these two residues alone resulted in only partial resistance to proteolysis (6) when B104 conditioned medium was the source of proteolytic activity.
The extended domain involved in proteolytic degradation raises questions about the nature of the IGFBP-4 proteases produced by smooth muscle. PAPP-A has recently been found to cleave IGFBP-4 in an IGF-dependent manner (22, 38) . Although this zinc-binding metalloproteinase also cleaves IG- FBP-5 (39), it is thought to represent the dominant IGFBP-4 protease in most systems examined so far (17, 22, 27, 40) . PAPP-A is expressed in porcine vascular smooth muscle cells in culture, and immunoreactive PAPP-A increases in the medium following arterial injury in pigs (23) . Furthermore, in a recent human study, PAPP-A protein abundance is increased in unstable coronary plaques and is detected by immunoassay at higher concentrations in patients with either unstable angina or acute myocardial infarction (41) . PAPP-A mRNA is also expressed in rodent vascular smooth muscle cells and in aortic tissue, and at least some of the IGFBP-4 protease activity detected in rat smooth muscle cell cultures is likely to be accounted for by PAPP-A (18). However, porcine smooth muscle IGFBP-4 protease activity appears to cleave IGFBP-4 at a distinct site from PAPP-A and has a different inhibitor profile (24) . Because of this discrepancy, and the presence of an extended cleavage domain in our studies, it is possible that there is more than one protease acting either individually or sequentially on IGFBP-4 to achieve complete degradation of the protein.
In accord with our previous report in which native IGFBP-4 was overexpressed under the control of the same SM ␣-actin promoter, the IGBP-4.7A mutant was expressed uniquely in smooth muscle-rich tissues (31) . All IGFBP-4.7A-expressing lines had a higher ratio of immunoreactive IGFBP-4 to mRNA than their IGFBP-4 wild type-overexpressing counterparts. This points to a key post-translational step in the regulation of IGFBP-4 abundance in vivo, almost certainly through regulated proteolysis. This binding protein is also subject to significant pretranslational regulation in smooth muscle cells. Thus IGFBP-4 mRNA levels are regulated by PDGF (42) , thrombin (43) , and angiotensin (43) in smooth muscle cells in vitro, and following in vivo perturbations such as bladder outlet obstruction (44), arterial injury (18) , and aortic coarctation (45) . The evidence presented here indicates that IGFBP-4.7A results in greater growth inhibition than equivalent levels of wild type IGFBP-4 in vivo. These results support the concept that proteolysis of IGFBP-4 may be required for release of free IGF-I in smooth muscle and that the growth factor may be sequestered if the binding protein cannot be readily degraded.
Despite the fact that IGFBP-4 consistently inhibits IGF action in many cell types in vitro, preliminary data on IGFBP-4-null mice indicate that, contrary to expectation, these animals have lower weight at birth (10 -15%) (46) . One potential explanation is that the absence of IGFBP-4 diminishes tissue IGF storage capacity. This would predict that physiological levels of IGFBP-4 are required for normal growth, and that IGFs would be released through the action of PAPP-A and perhaps other IGFBP-4 proteases. When IGFBP-4 is selectively overexpressed in vivo tissue hypoplasia ensues due to ligand sequestration, because the degradation rate is exceeded by higher local production (31) . Our present results further support this concept, because expression of a protease-resistant mutantbinding protein resulted in even greater growth suppression in the targeted tissue environments. Recent studies examining the effects of local infusions of IGFBP-4 in bone also support this notion. Injection of a protease-resistant IGFBP-4, in which the sequence His-121 to Pro-141 was deleted, directly into the parietal bone was more potent than wild-type IGFBP-4 in inhibiting the anabolic actions of IGF-I (26). IGFBP-4 also appears to play a role in transport of IGF-I across the endothelial barrier, an effect that may require proteolysis of the binding protein (26, 47, 48) . As IGFBP-4 proteolysis is also a step amenable to regulation (18, 23) ; coordinated IGFBP-4 biosynthesis and degradation may be required to allow appropriate delivery of free IGF-I to target tissues.
